Novozymes and
Chr. Hansen to combine
and create a leading global biosolutions partner
Key documents
Exemption document and related documents
Exemption document
Retail brochure (in Danish only)
Merger documents
Merger plan
Merger statement
Tax-exempt merger ruling
Auditor documents
Valuer’s report on the merger plan
Valuer’s report on the creditors’ position after merger
Extraordinary shareholder’s meeting March 30, 2023
Notice convening the extraordinary general meeting
Live streaming of extraordinary shareholders’ meeting
Live streaming of extraordinary shareholders’ meeting (in Danish)
Resolutions from extraordinary shareholders’ meeting
Minutes from extraordinary shareholders’ meeting
Announcements
Stock exchange announcement regarding approval of combination by Novozymes shareholders
Investor news on the approval of combination by the Novozymes shareholders and Chr. Hansen shareholders
Press release on the approval of combination by the Novozymes shareholders and Chr. Hansen shareholders
Investor news on U.S. antitrust regulation
Stock exchange announcement regarding exemption document
Stock exchange announcement regarding proposed merger
Press release regarding proposed merger
Presentation
Investor presentation (December 12, 2022)
Conference call (December 12, 2022)
Other documents
Draft amended articles of association for Novozymes
Draft articles of association for Novozymes after completion of the Merger
Revised remuneration policy
Novozymes Remuneration Report 2022
Novozymes Articles of Association (March 2, 2023)
Novozymes annual reports
The Novozymes Annual Report 2022
The Novozymes Annual Report 2021
The Novozymes Annual Report 2020
The Novozymes Annual Report 2019
Chr. Hansen annual reports
The Chr. Hansen Annual Report 2021/2022
The Chr. Hansen Annual Report 2020/2021
The Chr. Hansen Annual Report 2019/2020
FAQ
Factsheet
Contacts
Investor relations
Tobias Cornelius Björklund
Head of Investor relations
+45 3077 8682
tobb@novozymes.com